CD44 and breast carcinoma: This would further correlate with preliminary flow cytometry data showing that M13HS hybrid clone cells possess the breast cancer stem cell phenotype CD24−/lowCD44+ [51], which is conflicting to data of Grosse-Wilde et al. demonstrating that hybrid E/M cells that possess putative CS/IC properties were CD24+/CD44+ [49].